Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids

• US 9,422,593 B2
• Filed: 05/18/2011
• Issued: 08/23/2016
• Est. Priority Date: 05/19/2010
• Status: Expired due to Fees

• Current Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Original Assignee: QIAGEN Gaithersburg, Inc. (Qiagen NV)
• Inventors: Rothmann, Thomas, Nazarenko, Irina, O'Neil, Dominic, Virmani, Arvind, Lowe, Brian, Agarwal, Shiuli, Basham, Holly
• Primary Examiner(s): Lu, Frank
• Application Number:
  US13/110,660
• Publication Number:
  US 20120045756A1
• Time in Patent Office: 1,924 Days
• Field of Search: 435/6.1, 435/6.11, 435/6.12, 435/91.1, 435/91.2, 435/91.51, 436/94, 436/501, 436/544, 436/545, 436/546, 536/23.1, 536/24.3, 536/24.33, 536/25.3
• US Class Current: 1/1
• CPC Class Codes: C12Q 1/6806 Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay C12Q1/6804 takes precedence
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
• CPC Class Codes: C12Q 2563/107 fluorescence
• CPC Class Codes: C12Q 2565/518 characterised by the immobilisation of the nucleic acid sample or target
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Methods and materials for determining the presence of at least one nucleic acid in a sample are provided, said methods comprising (1) a purification step using sequence specific hybrid capture; (2) an amplification step; and (3) a detection step comprising contacting the target nucleic acid with a plurality of detectably labeled nucleic acid detection probes, wherein each (a) bears a different detectable label from the other detection probes, and/or (b) has a different melting temperature from probes bearing the same detectable label. Also disclosed are compositions and kits for use in such a method.

Claims

1. A method of detecting at least one target nucleic acid in a sample, said method comprising:

(A) generating at least one purified target nucleic acid by;

(A1) generating at least one double-stranded nucleic acid hybrid by hybridizing the at least one target nucleic acid in the sample to a hybrid probe set comprising at least a first nucleic acid probe specifically hybridized to the at least one target nucleic acid;

(A2) separating the at least one double-stranded nucleic acid hybrid from the sample, wherein the at least one double-stranded nucleic acid hybrid is the at least one purified target nucleic acid;

(B) amplifying at least a portion of the at least one purified target nucleic acid, thereby generating at least one amplified nucleic acid; and

(C) detecting the at least one target nucleic acid by;

(C1) contacting the at least one amplified nucleic acid with a detection probe set comprising at least three nucleic acid detection probes and forming at least one hybridization complex, wherein;

(C1(a)) each detection probe of the detection probe set bears a detectable fluorescent label;

(C1(b)) at least two detection probes of the detection probe set carry the same detectable fluorescent label;

(C1(c)) each probe carrying the same detectable fluorescent label of the detection probe set has a different melting temperature (T_m), and each probe having identical or very similar melting temperatures of the detection probe set carry a different fluorescent label; and

(C1(d) each detection probe of the detection probe set hybridizes to a different target nucleic acid sequence;

(C2) detecting and identifying the detectable fluorescent label of each detection probe of the detection probe set hybridized to the at least one amplified nucleic acid; and

(C3) detecting the temperature at which each detection probe of the detection probe set dissociates from the at least one amplified nucleic acid;

wherein the at least one target nucleic acid is detected based on the detectable fluorescent label of each detection probe of the detection probe set and the temperature which each detection probe of the detection probe set dissociates from its corresponding hybridization complex of the at least one hybridization complex.

2. The method of claim 1, wherein the at least one double-stranded nucleic acid hybrid is separated from the sample by binding a hybrid specific molecule to the at least one double-stranded nucleic acid hybrid.

3. The method of claim 2, wherein said binding of the hybrid specific molecule to the at least one double-stranded nucleic acid hybrid immobilizes the at least one purified target nucleic acid to a solid phase.

4. The method of claim 3, wherein the hybrid specific molecule is bound to or adapted to be bound to the solid phrase, wherein the solid phrase is a solid support.

5. The method of claim 3, wherein said amplifying at least a portion of the at least one purified target nucleic acid is performed after the at least one purified target nucleic acid is immobilized to the solid phase.

6. The method of claim 2, wherein the double-stranded nucleic acid hybrid is a DNA:

RNA hybrid and the hybrid specific molecule is an anti-DNA;

RNA hybrid antibody or a fragment thereof.

7. The method of claim 1, wherein said amplifying at least a portion of the at least one purified target nucleic acid is performed by an isothermal amplification.

8. The method of claim 7, wherein the isothermal amplification utilizes:

(a) a polymerase having strand displacement activity; and

(b) random primers.

9. The method of claim 8, wherein the at least one target nucleic acid comprises a whole genome and the isothermal amplification is a whole genome amplification.

10. The method of claim 1, wherein the melting temperatures of all probes carrying the same detectable fluorescent label of the detection probe set differ at least 0.1°

C.

11. The method of claim 1, wherein the melting temperatures of all probes carrying the same detectable fluorescent label of the detection probe set differ 0.5°

C. to 10°

C.

12. The method of claim 1, wherein the melting temperatures of all probes of the detection probe set differ about 5°

C.

13. The method of claim 1, wherein the detectable fluorescent label comprises at least one fluorophore selected from the group consisting of:

c1(d);

a fluorophore capable of being excited by an excitation source at 365±

20 nm and detected using a 460±

15 nm detection filter;

c1(e);

a fluorophore capable of being excited by an excitation source at 470±

10 nm and detected using a 510±

5 nm detection filter;

c1(f);

a fluorophore capable of being excited by an excitation source at 530±

5 nm and detected using a 555±

5 nm detection filter;

c1(g);

a fluorophore capable of being excited by an excitation source at 585±

5 nm and detected using a 610±

5 nm detection filter;

c1(h);

a fluorophore capable of being excited by an excitation source at 625±

10 nm and detected using a of 660±

10 nm detection filter; and

c1(i);

a fluorophore capable of being excited by an excitation source at 680±

5 nm and detected using a 712 nm long pass detection filter.

14. The method of claim 13, wherein the detection probe set comprises at least three groups of probes, wherein each probe of said at least three groups

comprises a fluorophore selected from the group consisting of c1 (d) to c1 (i);

and

one probe of said at least three groups has a melting temperature at least 0.1°

C. different from other probes of the same group of said at least three groups.

15. The method of claim 1, wherein the detection probe set comprises:

c1(d);

at least one detection probe specific for a ciprofloxacin resistance target selected from the group consisting of gyrA, gyrB-1, gyrB-2, parC, and parE; and

c1(e);

at least one detection probe specific for a genomic or plasmid target selected from the group consisting of capB2, capB4, pXO1, pXO2, PLA, PIM, CAF1, tul4, and fopA.

16. The method of claim 1, wherein the detection probe set comprises at least one detection probe specific for a nucleic acid derived from a pathogen selected from the group consisting of:

Mycobacterium tuberculosis, Streptococcus, Pseudomonas, Shigella, Campylobacter, Salmonella, Respiratory Syncytial Virus A, Respiratory Syncytial Virus B;

adenovirus, herpes simplex virus (HSV) 1, HSV2, Influenza A/B, hMPV Parainfluenzavirus 1-4, Coronavirus, Rhinovirus, Enterovirus, Bocavirus, cytomegalovirus (CMV), human immunodeficiency virus, influenza A virus subtype H1N1, chlamydia, Neisseria gonorrhoeae, Trichomonas vaginalis, Staphylococcus aureus, SARS-associated coronavirus, Escherichia coli, Bacillus anthracis, Ebolavirus, Marburgvirus, Yersinia pestis, Vibrio cholerae, F. tularensis, Brucella, Coxiella burnetii, Machupo virus, Coccidioides immitis, Coccidioides posadasii., Burkholderia mallei, Burkholderia pseudomallei, Shigella ssp. bacterium, Rickettsia rickettsii, Rickettsia prowazekii, Chlamydophila psittaci, yellow fever virus, Japanese encephalitis virus, Rift Valley fever virus, Variola major, and Variola minor.

17. The method of claim 1, wherein the amplifying and detecting steps are performed simultaneously.

18. The method of claim 1, wherein step (C3) further comprises determining the temperature which each detection probe of the detection probe set dissociates from its corresponding hybridization complex of the at least one hybridization complex which includes contacting the at least one amplified nucleic acid with a double stranded nucleic acid-specific dye.

19. The method of claim 18, wherein the double stranded nucleic acid-specific dye is selected from the group consisting of SYBR®

Green I, SYBR®

Gold, ethidium bromide, propidium iodide, Pico Green, Hoechst 33258, YO-PRO-I and YO-YO-I, SYTO®

9, LC Green®

, LC Green®

Plus+, and EvaGreen ™

.

20. A detection probe set comprising at least five nucleic acid probes specific for different target nucleic acids, each of the at least five nucleic acid probes comprising a detectable label, wherein:

(A) at least two of the nucleic acid probes of the at least five nucleic acid probes comprise the same detectable label;

(B) each probe carrying the same detectable label of the nucleic acid probes of the at least five nucleic acid probes has a different melting temperature; and

(C) the detectable label is a fluorophore selected from the group consisting of;

(C1);

a fluorophore capable of being excited by an excitation source at 365±

20 nm and detected using a 460±

15 nm detection filter;

(C2);

a fluorophore capable of being excited by an excitation source at 470±

10 nm and detected using a 510±

5 nm detection filter;

(C3);

a fluorophore capable of being excited by an excitation source at 530±

5 nm and detected using a 555±

5 nm detection filter;

(C4);

a fluorophore capable of being excited by an excitation source at 585±

5 nm and detected using a 610±

5 nm detection filter;

(C5);

a fluorophore capable of being excited by an excitation source at 625±

10 nm and detected using a of 660±

10 nm detection filter; and

(C6);

a fluorophore capable of being excited by an excitation source at 680±

5 nm and detected using a 712 nm long pass detection filter.

21. The detection probe set of claim 20, wherein the melting temperature of each of the at least five nucleic acid probes differs at least 0.1°

C.

22. The detection probe set of claim 20, wherein the melting temperature of each of the at least five nucleic acid probes differs 0.5°

C. to 10°

C.

23. The detection probe set of claim 20, wherein the melting temperature of each of the at least five nucleic acid probes differs about 5°

C.

24. A kit for detecting a target nucleic acid comprising:

(A) at least one hybrid capture probe;

(B) the detection probe set of claim 20; and

optionally comprising one or more of the following;

(C) a polymerase;

(D) a double stranded nucleic acid-specific dye;

(E) an anti-DNA-RNA hybrid antibody;

(F) a solid support capable of binding to the anti-hybrid antibody;

(G) a denaturation reagent;

(H) a helicase; and

(I) a reagent for fragmenting an amplified nucleic acid.